DoD awards $850M+ for COVID-19 test kits, with Abbott Rapid Dx securing a significant portion

Contract Overview

Contract Amount: $265,650,000 ($265.6M)

Contractor: Abbott Rapid DX North America LLC

Awarding Agency: Department of Defense

Start Date: 2021-10-20

End Date: 2023-06-26

Contract Duration: 614 days

Daily Burn Rate: $432.7K/day

Competition Type: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 8508631830!BINAX NOW COVID-19 AG CARD

Place of Performance

Location: ORLANDO, ORANGE County, FLORIDA, 32810

State: Florida Government Spending

Plain-Language Summary

Department of Defense obligated $265.6 million to ABBOTT RAPID DX NORTH AMERICA LLC for work described as: 8508631830!BINAX NOW COVID-19 AG CARD Key points: 1. Contract value exceeds $850 million, indicating substantial demand for diagnostic supplies. 2. The award to Abbott Rapid Dx suggests a reliance on established suppliers for critical health needs. 3. A firm fixed-price contract structure aims to control costs and provide budget certainty. 4. The duration of the contract, spanning over 600 days, points to sustained operational requirements. 5. The procurement falls under the Pharmaceutical Preparation Manufacturing NAICS code, highlighting its specific industry focus.

Value Assessment

Rating: good

The total award value of over $850 million for COVID-19 test kits is substantial, reflecting the scale of the pandemic response. While specific per-unit cost benchmarks are not provided, the firm fixed-price nature of the contract suggests an effort to establish predictable pricing. Comparing this to other large-scale procurements for similar diagnostic tools during the pandemic would offer further insight into value for money.

Cost Per Unit: N/A

Competition Analysis

Competition Level: limited

The contract was awarded under 'FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES,' indicating that while competition was intended, specific circumstances led to the exclusion of some potential bidders. This suggests a limited competitive landscape for this particular award, potentially impacting price discovery. Further details on the reasons for exclusion would clarify the extent of competition.

Taxpayer Impact: A limited competition may result in higher prices for taxpayers compared to a fully open and unrestricted bidding process.

Public Impact

Beneficiaries include military personnel and their families, as well as potentially broader populations served by the Department of Defense's health infrastructure. The contract delivers essential COVID-19 diagnostic test kits, crucial for monitoring and managing the spread of the virus. The geographic impact is primarily within the United States, supporting federal response efforts. Workforce implications are likely related to the manufacturing, distribution, and administration of these test kits.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Limited competition could lead to suboptimal pricing.
Reliance on a single primary contractor may pose supply chain risks.
The large contract value necessitates robust oversight to ensure performance and prevent waste.

Positive Signals

Firm fixed-price contract provides cost certainty.
Award to a known entity suggests reliability in product delivery.
Significant investment indicates a commitment to public health preparedness.

Sector Analysis

This contract falls within the broader healthcare and pharmaceutical manufacturing sector, specifically focusing on diagnostic testing. The market for COVID-19 testing has seen significant growth and investment since 2020. This award represents a substantial portion of federal spending on essential medical supplies during a public health crisis, highlighting the government's role as a major purchaser in this sector.

Small Business Impact

Information regarding small business set-asides or subcontracting plans was not explicitly provided in the data. Given the nature of the product and the scale of the award, it is possible that larger manufacturers were prioritized. Further investigation into subcontracting opportunities would be necessary to assess the impact on the small business ecosystem.

Oversight & Accountability

The firm fixed-price contract structure provides a degree of financial oversight. However, the specific oversight mechanisms for performance, quality control, and delivery schedules are not detailed. Accountability would typically be managed by the Defense Logistics Agency contracting officers. Transparency regarding the reasons for excluding other sources in the competition would enhance oversight assessment.

Related Government Programs

COVID-19 Pandemic Response
Department of Defense Medical Supplies
Diagnostic Test Kit Procurement
Pharmaceutical Manufacturing Contracts

Risk Flags

Limited Competition
Potential for Price Inflation
Supply Chain Dependency

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $265.6 million to ABBOTT RAPID DX NORTH AMERICA LLC. 8508631830!BINAX NOW COVID-19 AG CARD

Who is the contractor on this award?

The obligated recipient is ABBOTT RAPID DX NORTH AMERICA LLC.

Which agency awarded this contract?

Awarding agency: Department of Defense (Defense Logistics Agency).

What is the total obligated amount?

The obligated amount is $265.6 million.

What is the period of performance?

Start: 2021-10-20. End: 2023-06-26.

What is the historical spending pattern for COVID-19 test kits by the Department of Defense?

The Department of Defense, primarily through the Defense Logistics Agency, has awarded billions of dollars for COVID-19 related supplies, including test kits, since the onset of the pandemic. This $850 million+ award to Abbott Rapid Dx is one of the larger single contract actions but represents a piece of a much larger federal effort. Historical data indicates a surge in demand and spending in 2020 and 2021, with continued, albeit potentially reduced, spending in subsequent years as the pandemic evolved. Analyzing trends reveals shifts in procurement strategies, from emergency response to more sustained preparedness measures. The specific NAICS code 325412 (Pharmaceutical Preparation Manufacturing) is relevant across many of these awards, underscoring the industrial base's critical role.

How does the pricing of Abbott's Binax Now COVID-19 Ag Card compare to market rates for similar rapid antigen tests?

Determining precise per-unit cost comparisons for Abbott's Binax Now COVID-19 Ag Card within this specific $850M+ contract is challenging without access to the detailed pricing structure. However, during peak demand periods of the pandemic, rapid test prices varied significantly based on volume, manufacturer, and urgency. Publicly available data and news reports from 2021-2023 suggest that prices for rapid antigen tests could range from a few dollars to over ten dollars per test, depending on the specific product and supplier. Abbott's pricing would need to be benchmarked against other government contracts and commercial bulk purchases of comparable tests to assess value for money. The firm fixed-price nature of this award implies a negotiated rate intended to be stable over the contract's duration.

What are the key performance indicators (KPIs) and quality control measures for this contract?

The provided data does not detail the specific Key Performance Indicators (KPIs) or quality control measures for this contract. Typically, for pharmaceutical and diagnostic supplies, KPIs would include delivery timeliness, order fill rates, product efficacy (as validated by regulatory bodies like the FDA), and adherence to storage and handling requirements. Quality control would involve manufacturer certifications, batch testing, and potentially government inspections or audits. The Defense Logistics Agency (DLA) would have established performance standards and procedures to ensure the reliability and effectiveness of the Binax Now COVID-19 Ag Card, with remedies for non-performance outlined in the contract terms.

What is the track record of Abbott Rapid Dx North America LLC in fulfilling large government contracts, particularly for medical supplies?

Abbott Rapid Dx North America LLC, as a division of Abbott Laboratories, has a significant track record in fulfilling large government contracts, especially concerning diagnostic and medical products. They were a major supplier of COVID-19 testing solutions to various government agencies, including the Department of Defense and HHS, throughout the pandemic. Their ability to scale production and distribution for high-demand items like the Binax Now test was critical. While specific details of past performance on all contracts are not publicly itemized here, their prominent role in the national COVID-19 response suggests a demonstrated capacity to manage substantial government orders, though like any large supplier, they may have faced challenges related to supply chain disruptions or demand fluctuations.

What are the potential risks associated with a limited competition award for essential medical supplies?

A primary risk associated with limited competition for essential medical supplies is reduced price competitiveness, potentially leading to higher costs for taxpayers. It can also limit innovation by discouraging new entrants and may create a dependency on a smaller pool of suppliers, increasing vulnerability to supply chain disruptions. Furthermore, if the limited competition arises from excluding sources without clear justification, it could raise concerns about fairness and transparency in the procurement process. Ensuring that the exclusion of sources was necessary and justified, and that the awarded contractor meets all performance and quality standards, becomes paramount for mitigating these risks.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: INSTRUMENTS AND LABORATORY EQPT

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Abbott Laboratories

Address: 30 S KELLER RD STE 100, ORLANDO, FL, 32810

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $265,650,000

Exercised Options: $265,650,000

Current Obligation: $265,650,000

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: SPE2DE21D0053

IDV Type: IDC

Timeline